Thole J E, van Dalen P J, Havenith C E, Pouwels P H, Seegers J F, Tielen F D, van der Zee M D, Zegers N D, Shaw M
Special Program Infectious Diseases, TNO Prevention and Health, Zernikedreef 9, 2301 CE Leiden, The Netherlands.
Curr Opin Mol Ther. 2000 Feb;2(1):94-9.
By expression of foreign antigens in attenuated strains derived from bacterial pathogens and in non-pathogenic commensal bacteria, recombinant vaccines are being developed that aim to stimulate mucosal immunity. Recent advances in the pathogenesis and molecular biology of these bacteria have allowed rational development of new and improved bacterial carriers and more effective gene expression systems. These advances have improved the performance and versatility of these delivery systems to induce mucosal immunity to recombinant antigens in animal models. Application of these (improved) technologies for development of human vaccines is still limited and awaits further exploration.
通过在源自细菌病原体的减毒株和非致病性共生细菌中表达外源抗原，正在开发旨在刺激黏膜免疫的重组疫苗。这些细菌在发病机制和分子生物学方面的最新进展使得能够合理开发新的和改良的细菌载体以及更有效的基因表达系统。这些进展提高了这些递送系统在动物模型中诱导对重组抗原的黏膜免疫的性能和通用性。这些（改进的）技术在人类疫苗开发中的应用仍然有限，有待进一步探索。
